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Advances in the Diagnosis of Urothelial Neoplasia
John D. Crissman, MD,* Richard J. Zarbo, MD,* Terri Johnson, MD,*
V. Ramesh Babu, PhD,+ Fazlul H. Sarkar, PhD,* Brian J. Miles, MD,§ and
Joseph C. Cerny, MD§

Urothelial neoplasia is a unique cancer in that it consists ofa spectrum of tumors with different
biologic behaviors. The most common urothelial neoplasm is the low grade superficial papillary
carcinoma or papilloma which may recur numerous times but does not result in significant morbidity
or mortality. A variant ofthe superficial papillary carcinoma, which represents approximately 10% of
the tumors, is the noninvasive papillary neoplasm which progresses to a less differentiated invasive
transitional cell carcinoma (TCC). Considerable effort has been directed at identifying which of the
superficial well differentiated papillary tumors will persist, recur and progress to invasive cancer
Current approaches to identifying such tumors include cytogenetics, molecular biology, and flow
cytometric DNA analysis. In the final group of bladder carcinomas, the high grade invasive
neoplasms, evidence suggests that these life-threatening tumors arise de novo without identifiable
precursors. Unfortunately, 75% to 90% of invasive TCCs are classified in this group, with the
remaining minority progressing from preexisting recurrent superficial papillary carcinomas.
Obviously the biologic behavior ofthese aggressive poorly differentiated tumors is life-threatening,
and application of traditional diagnostic procedures and new technologies need to be directed at early
diagnosis. (Henry Ford Hosp MedJ 1989:37:19-23)

T

ransitional cell carcinoma (TCC) of the urinary bladder is a
relatively common neoplasm. The American Cancer Society estimates that 45,400 new cases of TCC will be diagnosed in
1989, accounting for 4.71% of new cancers and approximately
10,000 deaths. Death from TCC is invariably due to metastases
which are a direct sequelae of invasion into the bladder wall.
Large size and deep invasion correlate with the presence of metastatic disease. Unfortunately, the vast majority (75% to 90%)
of invasive TCCs develop de novo without a recognized precursor and only 10% to 25% are preceded by papillary noninvasive
TCC. The biologic progression of precursors and noninvasive
TCC is complex and not completely understood. Two separate
and distinct problems in diagnosing urothelial cancer involve 1)
early diagnosis of invasive high grade neoplasms, and 2) identification of predictors of recurrence/progression in patients with
noninvasive papillary TCC. Exfoliative urine cytology and
cystoscopy-directed biopsy with direct visualization of the affected urothelium remain the standards for diagnosis and classification of TCC.
At initial diagnosis approximately 75% of TCCs are noninvasive tumors (Ta), although some will have microinvasion into
the lamina propria (Tl). These neoplasms are regarded as superficial tumors and, although symptomatic, are generally not considered life-threatening. Most noninvasive papillary TCCs are

Henry Ford Hosp Med J—Vol 37. No 1. 1989

well differentiated grade 1 neoplasms with histologic (and
cytologic) appearances similar to hyperplastic urothelium. Unfortunately, approximately two-thirds of these patients will develop recurrent tumors, and 10% to 20% of these recurrences
will have a less differentiated histologic grade and/or invade into
the lamina propria or muscle layers of the bladder. Parameters
associated with recurrence and/or progression include 1) multifocal tumors, 2) coexisting severe dysplasia/carcinoma in situ
(CIS), 3) loss of differentiation antigens such as blood group related antigens (BGRA), 4) development of marker chromosomes or abnormal cellular DNA content measured by flow
cytometry or image analysis systems, and 5) histologic
(cytologic) dedifferentiation to a higher grade. The last three
factors are closely related as loss of expression of differentiation
antigens is associated with development of marker chromosome
abnormalities and deviation from normal (diploid) DNA con-
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tent. These genetic changes usually result in morphologic loss
of differentiation. We present the current status of diagnostic
procedures and techniques available for classification of TCC,
as well as our experience at Henry Ford Hospital in the application of new technologies that are being studied in numerous
institutions.

Pathology

sion. Nevertheless, most invasive urothelial TCCs are not associated with or preceded by papillary TCC (8). In a series of 104
patients with invasive TCC, only 20 had histories of preceding
papillary (noninvasive) tumors (8). This infrequent progression
of papillary tumors has been observed by others (5), and thus it is
generally accepted that the majority of invasive TCCs appear de
novo, without a preceding diagnosis of urothelial pathology.

Cytology

The surgical pathology of urothelial neoplasia can be divided
into three major groups. The most common is the papillary
(noninvasive) urothelial tumor which represents approximately
75% of TCC diagnosed. These neoplasms consist of a proliferation of urothelium which is cytologically similar in appearance
to normal or hyperplastic urothelium and are well differentiated/
grade I TCC. The propensity to proliferate (but not invade) leads
to an exophytic growth above the adjacent mucosa into the bladder lumen, resulting in the characteristic appearance at
cystoscopy. The exophytic and orderly growth of differentiated
papillary urothelial neoplasms is a central fibrovascular core
providing blood supply and mechanical support of the expanding neoplastic urothelium. The well differentiated nature (grade
I) of the majority of papillary urothelial neoplasms is reflected
by the difficulties in cytologic diagnosis. Exfoliated cells from
grade 1 papillary neoplasms are morphologically similar to cells
shed from nonneoplastic inflammatory/reactive or normal
urothelium. Urinary tract instrumentation or nephrolithiasis/
urolithiasis may also result in exfoliation of cells, resulting in a
cytologic picture indistinguishable from grade I TCC. The diagnosis of well differentiated papillary tumors requires cystoscopy
with biopsy confirmation. Many patients will have numerous recurrences of papillary urothelial neoplasms, either in the same
site (persistence) or at other sites of the urothelium (recurrence).
Some evidence indicates that patients with severe dysplasia or
CIS in the adjacent, normal-appearing urothelium are more
likely to have recurrent neoplasms (1-3). The National Bladder
Cancer Collaborative Group concluded that coexisting severe
dysplasia/CIS at sites removed from the papillary tumor are at
even higher risk for progression to invasive cancer (3,4). A second group of patients likely to develop invasive carcinoma are
those who have recurrent papillary neoplasms with a less differentiated histologic grade (5). Although the frequency of progression to invasive cancer in patients with dysplasia/CIS is not
accurately defined, it is unquestionably substantial. In one series, 42% of patients with differentiated papillary tumors and
coexisting CIS developed invasive cancer over a 42-month
period (6).

Urinary cytology is a valuable diagnostic tool in the detection
and follow-up of patients with urothelial neoplasms. Cytology is
diagnostic of high grade neoplasias, either in situ, papillary, or
invasive. Cytologic evaluation can be made from a variety of
specimens including voided urine or urine collected by instrumentation, such as catheterization or cystoscopy and bladder/
urethral/ureteral washings or brushings. The diagnostic yield
and accuracy depend on the method of specimen collection,
cytopreparatory technique, histologic grade of the neoplasm,
and the skill of the cytopathologist.
In a hypertonic environment such as urine, exfoliated cells
rapidly degenerate. Hence, a 24-hour specimen or a first moming sample is suboptimal for cytologic evaluation. This is also
necessary for urine from a catheter collection bag or for voided
urine that contains residual urine in patients with obstructive
uropathy. A voided urine sample must be submitted fresh to the
laboratory and processed immediately. If delay is anticipated,
the urine specimen may be fixed in an equal amount of 50%
ethyl alcohol and refrigerated. The best method can be chosen
with consultation of the cytopathologist. The advantage of the
voided specimen is that it can be easily collected and repeated
without any invasive techniques.
Instrumentation can dislodge large numbers of benign epithelial cells, both isolated and in tissue fragments. The latter
may also be seen in the presence of urolithiasis. In a fluid environment these tissue fragments of benign epithelium can assume a papillary configuration and are extremely difficult to differentiate from epithelial tissue fragments exfoliated from low
grade well differentiated urothelial neoplasms. A history of instrumentation or urolithiasis represents situations where falsepositive diagnosis of well differentiated (grade I) TCC can occur Indeed, the presence of benign-appearing tissue fragments
of transitional epithelium in a voided urine sample is abnormal
and indicative of grade I carcinoma, particularly in a patient
with no history of recent instrumentation or lithiasis. It is critical
that such a history be reported to the cytopathologists in order to
avoid a false-positive diagnosis.

Invasive TCC represents the stage of disease responsible for
tumor-related deaths. Generally invasive TCCs are poorly differentiated, high grade (III) neoplasms (5). Curiously, early
focal or microscopic invasion into the submucosa or lamina propria (stage A) is not considered life-threatening because these
tumors are not associated with significant frequency of regional
or distant metastases and are often grouped with other "superficial" forms of TCC. However, one series found that 30% of
stage A (microinvasive) TCC progressed to muscle invasion
over an average follow-up j>eriod of 39 months (7). This observation supports the ominous nature of any form of tumor inva-

Diagnostic yield and accuracy depend greatly on the histologic grade of the tumor. With adequate sample, almost all high
grade TCCs (in situ, invasive, or rarely papillary) can be identified from cytologic evaluation since malignant cells exfoliating
from these lesions present with definite, recognizable criteria.
Grade I (noninvasive) TCCs lack most of the morphologic
features of malignancy. They spontaneously exfoliate fewer
cells because of their intercellular attachments associated with
differentiation. In cytologic presentation, these neoplasms show
tight cell clusters, rather than single cells, as the tips of the
papillary fronds break off easily. The frequency offindingthese
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papillarytissuefragments depends on the size of the neoplasm
and to some extent on the tumor's location. The cytomorphology
of these cells resembles normal urothelium so closely that their
cytologic detection is reportedly low, ranging from zero (9) to
33% (10). The cells of grade I TCC present subtle cellular and
nuclear abnormalities such as mildly increased nuclear size, increased chromatin content with granularity, and irregularity of
the nuclear membrane and nucleoli. By considering such features. Murphy et al (11) reported 70% diagnostic accuracy for
grade 1 carcinomas. Grade II TCCs form a spectrum in-between
grade I and grade III. The exfoliated cells usually show sufficient cellular atypia to be detected in urinary samples. The reported diagnostic accuracy of cytology in grades II and III neoplasms varies greatly, with reports ranging from 51% (9), to 73%
(10), and 94% (11) of patients diagnosed.
Urinary cytology, especially bladder washing, is a reliable diagnostic test in identifying CIS. These intraepithelial carcinomas may be difficult to visualize by cytoscopy and often require random biopsies for diagnosis. The malignant cells from
CIS or invasive TCC are generally high grade and readily detectable by cytology. CIS exfoliates large numbers of single cells,
allowing their identification in virtually 100% of cases. However, the presence of high grade malignant cells does not indicate
the presence or absence of invasion, and the differentiation of
CIS and invasive carcinoma requires cystoscopy examination.
Urinary cytology is useful in monitoring patients with a history of TCC, particularly those cases which progress to less differentiated neoplasms. Bladder wash specimens sample a large
proportion of the bladder mucosa and have the potential to idenfify nonvisualized foci of CIS.

Urothelial Surface Antigens

with ABO(H) expression in patients with superficial, low grade
TCC. Deletion of the ABO(H) group and expression of T antigen predicts progression and tumor invasion with greater accuracy than ABO(H) deletion alone (17). The detection o f T
antigen also is best when performed on fresh or optimum-fixed
cells or on tissue biopsy and is unreliable in formalin-fixed, paraffin-embedded biopsies.

DNA Content and Distribution
Evaluating urothelial neoplasms for DNA content is also
helpful in the diagnosis and characterization of bladder tumors.
The optimum technique for measurement of DNA in tumor cells
is by staining with DNA dyes, such as propidium iodide, and
quantitating the DNA content of individual cells using flow
cytometric analysis. This new technology requires single cell
suspensions which complicates analysis of solid tumors but is
easily adapted for examination of urine, especially bladder
washes containing large numbers of single cells. The instrument
uses an exciting light (laser) which results in excitation of the
DNA dye (orfluoresceinatedantibody, etc) with the emission of
a light of specific wave length. The emitted light for each event
(cell) is measured by photosensitive light tubes and analyzed by
computer. In this manner, the instrument is capable of analyzing
hundreds of cells per second.
DNA analysis by flow cytometry is capable of measuring two
major parameters: the total DNA content of the tumor cell population, and the fraction of cells synthesizing DNA (specificpathogen free [SPE]). The former is calculated relative to expected DNA content of normal (diploid) cells that contain 46
chromosomes and is expressed as the DNA index. For instance,
a DNA index of 1 is normal; less than or greater than 1 reflects
loss or increase of chromosomal material and is abnormal
(aneuploid). The SPF is expressed as a fraction of the tumor cell
population which is synthesizing DNA; the greater this percentage, the more cells that are actively synthesizing DNA and presumably actively proliferating.
Flow cytometry is a technologic advance that can quantitatively measure subcellular changes not evident with the light
microscope. Using propidium iodide, which differentially
stains DNA, cellular changes in DNA content (ploidy) can
be quantitatively measured in single cell suspensions (18). In
our study of 75 bladder washings comparing flow cytometric
DNA analysis of ethanol-fixed cells with cytospin prepared
Papanicolaou (standard) cytologic analysis, 45% of the samples
examined had normal cytology but contained abnormal DNA
(hyperdiploid and tetraploid) (19). Abnormal DNA content is an
indicator for the aggressive potential of bladder tumor cells
since it is associated with higher histologic grades II and III and
a higher frequency of progression to invasion (20,21) (Table 1).
Thus, flow cytometry is useful in monitoring patients with
known bladder carcinomas and may predict the papillary tumors
likely to progress to invasive TCC if sufficient chromosomal
abnormalities exist.

Epithelial cells express differentiation antigens on their membrane surface, including the blood group related ABO(H) and
histocompatibility antigens. The expression of these antigens
reflects a complicated biochemical pathway beginning with the
gene(s) coding for the antigen, gene transcription, and protein
synthesis and transport through the cytoplasm to the membrane
surface. With some tumors progressing from papillary (noninvasive) to invasive TCC, a loss of BGRA occurs. This loss most
likely reflects genetic alterations with either loss of the specific
loci coding for BGRA or a defect in the transcription, synthesis,
or transport phase.
Bergman and Javadpour (12) and Lange et al (13) demonstrated that ABO(H) antigen deletion correlated with advanced
grade and stage of disease. Unfortunately, ABO(H) antigens are
extremely sensitive to glycolipid extracting solvents, and the detection of these antigens is optimum only on fresh or frozen cells
(14). Application of ABO(H) detection loses sensitivity when
applied to formalin-fixed, paraffin-embedded biopsies of
urothelial neoplasms (15).
Acquisition or expression of T antigen (ThomsenFriedenreich) (16) appears to represent another surface antigen
with prognostic value. T antigen is related to the M and N group
on nonnal erythrocytes and can be unmasked by removal of terminal sialic acid residues with neuraminidase. The presence of
Cytogenetics
T antigen is abnormal and is expressed primarily in high grade
Cytogenetic markers are established parameters for the diagTCC. The greatest value of T antigen detection is in combination nosis and management of patients with hematologic disorders.
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Table 1
Urothelial Neoplasia: Henry Ford Hospital Experience*

Table 2
Relation of Blood Group Related Antigen, H-Ras Product
(p21), and DNA Studies: Henry Ford Hospital Experience*

Grade
Histologic Grade

I

n

III

Tumor Cells Positive

Noninvasive (Ta)
Submucosal invasion (Tl)
Muscle invasion (T2 -t-)
Diploid range DNA
Aneuploid DNA
Total

4
0
0
4

7
2
0
8
1
9

0
1
12
2
11
13

Diploid range DNA (14)
Normal cytogenetics (4)
Abnormal cytogenetics (9)
Aneuploid DNA (12)
Cystitis (8)

()
4

*From Crissman JD, Liu BS, Zarbo RJ, et al. Diagnosis of urothelial neoplasia. Cytometry 1988;2(suppl):8.

Several characteristic markers have been identified in lymphomas and leukemias, such as the translocation (15,17)—a specific rearrangement for acute promyelocytic leukemia. This
chromosome change has not been described in any other form of
cancer. 'Virtually all subgroups of acute nonlymphocytic leukemias have been further classified based on the presence of specific chromosome markers. The application of cytogenetic
marker studies in hematopoietic neoplasms has progressed; cooperative cancer study groups are developing protocols for
clinical trials stratified by cytogenetic study. Technical limitations have hampered progress in the cytogenetics of solid tumors. Improvements in tissue culture including tumor disaggregation by enzyme digestion, application of enriched media,
and synchronization of cells in culture have contributed to advances in cytogenetic studies of solid tumors including TCC.
The value of chromosome analysis as a prognostic factor in
patients with TCC was recognized as eariy as 1971 by Falor and
Ward. Marker chromosomes predicted for tumor recurrence in a
later follow-up study by the same investigators (22). Trisomy 7
and monosomy 9 have been established as primary markers in
bladder cancer because these two changes were observed as sole
abnormalities in some tumors (23). Establishing primary and
secondary chromosome abnormalities for any tumor type is
important because they may be involved in initiation and/or progression of the tumor. We identified several nonrandom changes
in TCC: deletion of short arm (p) of chromosome 11, duplication
of 3p, deletion of long arm (q) of 6, trisomy 7, and duplication of
lq (24). Trisomy 7 is a good candidate for a primary genetic
event, whereas others are most likely secondary changes. In addition, tumors with lip deletion and 3p duplication were associated with a higher likelihood of tumor progression. We continue
to perform cytogenetic analysis on all bladder tumors in an attempt to better define chromosomal abnormalities of prognostic
value (Table 2).

Oncogenes as Himor Markers
Oncogenes are genes that cause or are associated with cancer.
They represent altered versions of a group of normal genes
(proto-oncogenes) that exist in every cell. When these protooncogenes are changed by point mutations or by translocation
from their usual position on one chromosome to another or have
their transcription-initiation sites altered, they may produce a
protein with a different configuration, an excess of their protein
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ABH (%)

T (%)

p2I (%)

50.0
29.4
40.0
27.9
33.6

19.8
17.4
20.6
14.6
13.4

56.0
67.0
49.0
40.3
16.6

*From Crissman JD, Liu BS. Zarbo RJ. et £ Diagnosis of urothelial neoplasia. Cytometry I988;2(suppl):8.

product, or may express this product at an inappropriate time of
the cell cycle. These changes have been shown to confer transforming properties leading to neoplasia, and therefore these altered genes are referred to as oncogenes (25-27).
DNA from certain naturally occurring human tumors can induce malignant transformation in the NIH-3T3 fibroblast cell
line. The first oncogene identified in a human tumor was the ras
oncogene, which was isolated from a human bladder cancer cell
line. Examination of the ras gene identified in the bladder cancer cell line indicates that a point mutation at codon 12 is responsible for its transforming capabilities. This mutation has been
found in some other human cancers including lung and colon
carcinomas. Slamon et al (28) demonstrated cellular oncogene
activity in tissues obtained from fresh human tumors. They
studied tumors from 54 patients representing 20 different cell
types and tested for the presence of 15 different oncogenes. The
ras oncogene, as well as myc and fos oncogenes, were expressed
in nearly all of the tumors studied. Other oncogenes were expressed infrequently, and some were not detected. Recent studies using restriction fragment length polymorphism (RFLP) of
the human C-Ha-ras-1 gene indicated the association of variable
tandem repeat sequences in some cancer patients with the possession of a rare Ha-ras allele (29,30). A similar association between rare alleles of C-mos and certain human cancers has also
been reported (31,32), providing further evidence for the
usefulness of RFLPs at proto-oncogene loci in determining predisposition of certain cancers including urothelial neoplasia.
The ras oncogene produces an immunogenic protein (p21)
that can be used to generate antibodies which can recognize this
oncogene product. The nature of bladder cancer invites application of monoclonal antibody techniques for early diagnosis and
monitoring of disease since it is readily sampled. We have identified that p21 expression is a better monitor of neoplastic cell
populations than BGRA deletions or expression of T antigen
(33) (Table 2). Urothelial carcinomas arise in the superficial lining of the urinary tract, and these neoplastic cells are bathed
constantly in urine and exfoliate readily. Cellular metabolites of
the cancer may also be presumed to be secreted or shed into the
urine. Using antisera generated against the ras oncogene product, we have identified ras oncoproteins in urine of patients with
TCC. Using an immunologic assay (enzyme-linked immunosorbent assay), we have demonstrated the presence of ras
expression in urine in 70% of patients with bladder cancer. Furthermore, increased level of ras expression was associated with
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higher tumor grade and increasing stage. We also detected the
ras oncogene product within the cytoplasm of exfoliated tumor
cells in patients with elevated ras oncoprotein expression in their
urine.
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